Brokers Issue Forecasts for Arrowhead Pharmaceuticals Inc’s FY2018 Earnings (ARWR)

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) – Investment analysts at Cantor Fitzgerald issued their FY2018 earnings per share estimates for Arrowhead Pharmaceuticals in a report issued on Monday. Cantor Fitzgerald analyst E. Piros forecasts that the biotechnology company will earn ($0.66) per share for the year. Cantor Fitzgerald currently has a “Neutral” rating and a $5.00 target price on the stock.

A number of other equities analysts have also recently commented on ARWR. Piper Jaffray Companies raised Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price target for the company in a report on Monday, November 27th. ValuEngine raised Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. BidaskClub lowered Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. B. Riley began coverage on Arrowhead Pharmaceuticals in a research report on Friday, January 5th. They set a “neutral” rating and a $3.00 price objective on the stock. Finally, Chardan Capital restated a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 16th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $4.13.

Arrowhead Pharmaceuticals (ARWR) traded down $0.15 during trading on Wednesday, hitting $5.16. The stock had a trading volume of 2,050,500 shares, compared to its average volume of 2,234,830. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.63 and a quick ratio of 3.63. Arrowhead Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $6.75. The firm has a market cap of $384.99, a PE ratio of -11.24 and a beta of 2.52.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Tuesday, December 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Arrowhead Pharmaceuticals had a negative return on equity of 40.38% and a negative net margin of 116.17%. The business had revenue of $8.71 million for the quarter, compared to analyst estimates of $7.32 million.

In related news, COO Bruce D. Given sold 20,000 shares of the business’s stock in a transaction on Monday, January 1st. The stock was sold at an average price of $3.69, for a total transaction of $73,800.00. Following the sale, the chief operating officer now owns 948,356 shares in the company, valued at approximately $3,499,433.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.60% of the company’s stock.

A number of hedge funds have recently modified their holdings of ARWR. OppenheimerFunds Inc. grew its position in Arrowhead Pharmaceuticals by 110.0% during the 4th quarter. OppenheimerFunds Inc. now owns 6,300,000 shares of the biotechnology company’s stock worth $23,184,000 after acquiring an additional 3,300,000 shares during the last quarter. First Manhattan Co. bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth $11,707,000. ING Groep NV bought a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth $3,500,000. Allianz Asset Management GmbH bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $1,958,000. Finally, Alps Advisors Inc. bought a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $305,000. Institutional investors and hedge funds own 20.48% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Brokers Issue Forecasts for Arrowhead Pharmaceuticals Inc’s FY2018 Earnings (ARWR)” was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/14/brokers-issue-forecasts-for-arrowhead-pharmaceuticals-incs-fy2018-earnings-arwr.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply